Will Morton[email protected]RSNA 2025PET/CT identifies Pluvicto patients at risk of adverse eventsThe finding is from an analysis of 237 patients undergoing treatment for metastatic castrate-resistant prostate cancer.December 2, 2025Page 1 of 1Top StoriesRSNA 2025PET/CT identifies Pluvicto patients at risk of adverse eventsThe finding is from an analysis of 237 patients undergoing treatment for metastatic castrate-resistant prostate cancer.RSNA 2025AI's performance in clinical settings may differ from literatureRSNA 2025Radiology must persevere in sustainability effortsRSNA 2025Mirai shows changes over time for breast cancer predictionRSNA 2025SPECT/CT predicts how patients respond to Pluvicto